Citations

Showing 10 of 108083 citations.

Impact of metformin on hypertension; current knowledge
Bakhshaei, Sina , Bakhshaei, Bina , Korani, Setayesh Sotoudehnia , Alamouti-fard, Emad, Allamiaghmiouni, Leila , Neshat, Sina , Sotoudehnia, Setayesh , Bakhshaei, Sina

Mayo Clinic

Journal of Renal Endocrinology | February 15, 2023 | Volume: 8 | Issue: No issue available | Pages: e25067

10.34172/jre.2022.25067 Get It

High blood pressure is a potential adjustable risk factor for vascular complications of diabetes. Numerous categories of anti-hypertensive medications have proven to effectively reduce these complications. Additionally, metformin, besides lowering glucose and lipid levels, has advantages on vascular blood flow and improving endothelial function. In this review, we investigate the potential benefits of metformin in lowering blood pressure. Previous studies suggested that the administration of metformin to non-diabetic patients could efficiently reduce systolic blood pressure. The whole comparison of the evidence shows that metformin may have small effects on lowering blood pressure; however, this effect is not directly via a change in sympathetic activity. Mechanisms of blood pressure reduction by metformin may be due to its indirect effects on insulin resistance, nephroprotective, cardioprotective, improvement of the sympatric nerve system, and endothelial function.
NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022
Saad, Ayman , Loren, Alison W. , Bolaños‐Meade, Javier , Chen, George , Couriel, Daniel R. , Stasi, Antonio Di , El‐Jawahri, Areej , Elmariah, Hany , Gundabolu, Krishna , Gutman, Jonathan A. , Ho, Vincent T. , Hoeg, Rasmus T. , Horwitz, Mitchell E. , Hsu, Joe L. , Dabaja, Mohamed Kharfan, Magenau, John, Martin, Thomas , Moreira, Jonathan , Nakamura, Ryotaro , Ninos, Cameron , Oliai, Caspian , Patel, Seema M., Randolph, Brion, Tzachanis, Dimitrios , Varshavsky‐Yanovsky, Asya, Vusirikala, Madhuri , Algieri, Frankie, Pluchino, Lenora A. , Kharfan Dabaja, Mohamed, Saad, Ayman , Elmariah, Hany , Farag, Sherif Shafik , Kassim, Adetola A , Mielcarek, Marco B. , Nieto, Yago , Oliai, Caspian H , Schroeder, Mark A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 15, 2023 | Volume: 21 | Issue: 2 | Pages: 108-115

10.6004/jnccn.2023.0007 | PMID 36791762 Get It

The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease—a major complication of allogeneic HCT—to enable the patient and clinician to assess management options in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.
The International Standards for Neurological Classification of Spinal Cord Injury: Classification Accuracy and Challenges
Snider, Brittany , Eren, Fatma, Reeves, Ronald K. , Rupp, Rüdiger , Kirshblum, Steven

Mayo Clinic

Topics in Spinal Cord Injury Rehabilitation | February 15, 2023 | Volume: 29 | Issue: 1 | Pages: 1-15

10.46292/sci22-00036 | PMID 36819931 Get It

Background Successful utilization of the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) requires a comprehensive understanding of its rules, terminology, and several complex concepts. There have been no studies investigating classification accuracy since the newest ISNCSCI revision (2019). Objectives To evaluate classification accuracy of SCI professionals using the 2019 ISNCSCI edition, identify common mistakes and areas of confusion, and assess associations between experience in ISNCSCI classification and performance. Methods Members of the International Spinal Cord Society (ISCoS) and attendees of the ISCoS Annual Scientific Meeting 2021 were invited to complete an online survey that included six ISNCSCI cases to classify. Results A total of 107 persons completed the survey, with overall classification accuracy of 74.6%. Accuracy was highest for injury completeness (95.3%) and sensory level (91.1%) and lowest for motor zone of partial preservation (ZPP; 54.7%) and ASIA Impairment Scale (AIS) grade (57.3%). Newer concepts, including the appropriate documentation of non-SCI conditions and classification of ZPP in incomplete injuries, contributed to several common errors. There was a significant association between overall classification accuracy and self-rated experience in the ISNCSCI classification ( p = .017). Experience with the ISNCSCI examination, experience in SCI medicine, and occupation were not found to be significantly associated with overall classification accuracy. Conclusion Classification accuracy of an international cohort of SCI professionals was modest but greater than previous reports. Knowledge deficits about the 2019 ISNCSCI updates are prevalent and contribute to common classification errors. Further training in the utilization of the ISNCSCI is needed.
IgA vasculitis nephritis (Schönlein-Henoch purpura with nephritis) following COVID-19 vaccination
Mahmoodnia, Leila , Savadjani, Shahin Asgari , Mostafavi, Leila , Korani, Setayesh Sotoudehnia , Chafjiri, Fatemeh Mohammad Alizadeh , Moghadam, Mahshid Sadat Chenarani , Jahantigh, Hamid Reza , Neshat, Sina , Shirbacheh, Ali , Baharani, Jyoti , Masomi, Rohollah , Hotkani, Zahra Golestani , Sotoudehnia, Setayesh

Mayo Clinic

Journal of Nephropathology | February 15, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.34172/jnp.2023.21447 Get It

IgA vasculitis nephritis (Schönlein-Henoch purpura nephritis) is an autoimmune circumstance characterized by palpable purpura involving the lower limbs, arthralgia, abdominal pain and kidney involvement. It is possible that a cytokine storm following coronavirus disease 2019 (COVID-19) could lead to an immunological dysregulation responsible for IgA vasculitis nephritis in these cases. Reactivation or first onset of IgA vasculitis nephritis is uncommon; however, there have been increasing reports of this disease, as a complication of COVID-19 vaccination. It is possible that COVID-19 mRNA vaccination may trigger several auto-inflammatory and autoimmune cascades. Previous research has shown that Toll-like receptors play a role in the development of IgA vasculitis nephritis. Following injection of a COVID-19 mRNA vaccine, the uptake of double-stranded RNA by-products will trigger Toll-like receptors, leading to a series of intracellular cascades starting an innate immunity-driven process of cell-mediated and humoral- mediated immunity.
Cochlear Implantation Outcomes in Adults With Single-Sided Deafness: A Systematic Review and Meta-analysis
Daher, Ghazal S. , Kocharyan, Arminé , Carlson, Matthew L. , Dillon, Margaret T.

Mayo Clinic

Otology & Neurotology | February 15, 2023 | Volume: 44 | Issue: 4 | Pages: 297-309

10.1097/mao.0000000000003833 | PMID 36791341 Get It

Objective To assess spatial hearing, tinnitus, and quality-of-life outcomes in adults with single-sided deafness (SSD) who underwent cochlear implantation. Databases Reviewed PubMed, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus databases were searched from January 2008 to September 2021 following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Methods Studies reporting spatial hearing, tinnitus, and quality-of-life outcomes in adult cochlear implant (CI) recipients (≥18 yr old) with SSD were evaluated. Study characteristics, demographic data, spatial hearing (speech recognition in noise, sound source localization), tinnitus (severity, loudness), and quality-of-life outcomes were collected. Results From an initial search of 1,147 articles, 36 studies that evaluated CI use in 796 unique adults with SSD (51.3 ± 12.4 yr of age at time of implantation) were included. The mean duration of deafness was 6.2 ± 9.6 years. There was evidence of improvement for speech recognition in noise using different target-to-masker spatial configurations, with the largest benefit observed for target-to-masker configurations assessing head shadow (mean, 1.87–6.2 dB signal-to-noise ratio). Sound source localization, quantified as root-mean-squared error, improved with CI use (mean difference [MD], −25.3 degrees; 95% confidence interval [95% CI], −35.9 to −14.6 degrees; p < 0.001). Also, CI users reported a significant reduction in tinnitus severity as measured with the Tinnitus Handicap Inventory (MD, −29.97; 95% CI, −43.9 to −16.1; p < 0.001) and an improvement in spatial hearing abilities as measured with the Spatial, Speech, and Qualities of Hearing questionnaire (MD, 2.3; 95% CI, 1.7 to 2.8; p < 0.001). Conclusions Cochlear implantation and CI use consistently offer improvements in speech recognition in noise, sound source localization, tinnitus, and perceived quality of life in adults with SSD.
Diagnosis and Management of Cyclic Vomiting Syndrome: A Critical Review
Frazier, Rosita , Li, B U.K. , Venkatesan, Thangam , Li, B U K , Venkatesan, Thangam , Frazier, Rosita D

Mayo Clinic

American Journal of Gastroenterology | February 15, 2023 | Volume: 118 | Issue: 7 | Pages: 1157-1167

10.14309/ajg.0000000000002216 | PMID 36791365 Get It

Cyclic vomiting syndrome (CVS) is a chronic disorder of gut-brain interaction characterized by recurrent disabling episodes of nausea, vomiting, and abdominal pain. CVS affects both children and adults with a prevalence of approximately 2% in the United States. CVS is more common in female individuals and affects all races. The pathophysiology of CVS is unknown and a combination of genetic, environmental, autonomic, and neurohormonal factors is believed to play a role. CVS is also closely associated with migraine headaches and likely have a shared pathophysiology. The diagnosis of CVS is based on the Rome criteria, and minimal recommended testing includes an upper endoscopy and imaging studies of the abdomen. CVS is frequently associated with anxiety, depression, and autonomic dysfunction. Patients with CVS commonly use cannabis therapeutically for symptom relief. By contrast, cannabinoid hyperemesis syndrome is believed to be a subset of CVS with chronic heavy cannabis use leading to hyperemesis. Due to the recalcitrant nature of the illness, patients often visit the emergency department and are hospitalized for acute CVS flares. Guidelines on the management of CVS recommend a biopsychosocial approach. Prophylactic therapy consists of tricyclic antidepressants (amitriptyline), antiepileptics (topiramate), and aprepitant in refractory patients. Abortive therapy consists of triptans, antiemetics (ondansetron), and sedation. Treatment of comorbid conditions is extremely important to improve overall patient outcomes. CVS has a significant negative impact on patients, families, and the healthcare system, and future research to understand its pathophysiology and develop targeted therapies is needed.
Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network
Schuster, Anne L. R. , Crossnohere, Norah L. , Bachini, Melinda , Blair, Cindy K. , Carpten, John D. , Claus, Elizabeth B. , Colditz, Graham A. , Ding, Li , Drake, Bettina F. , Fields, Ryan C. , Janeway, Katherine A. , Kwan, Bethany M. , Lenz, Heinz‐Josef , Mishra, Shiraz I. , Ricker, Charité , Sussman, Andrew L. , Tiner, Jessica C. , Trent, Jeffrey M. , Verhaak, Roel G.W. , Wagle, Nikhil , Bridges, John F. P. , Network, for the Participant Engagement and Cancer Genome Sequencing (PE-CGS), Schuster, Anne Lr , Ma, Qin , Mishra, Shiraz I , Paskett, Electra D , Rebbeck, Timothy R , Ricker, Charité , Stern, Mariana Carla , Sussman, Andrew L , Tiner, Jessica C , Trent, Jeffrey M , Verhaak, Roel Gw , Wagle, Nikhil , Willman, Cheryl , Bridges, John Fp , Colditz, Graham A , Bachini, Melinda , Paskett, Electra D. , Rebbeck, Timothy R. , Willman, Cheryl L. , Network, for the Participant Engagement and Cancer Genome Sequencing (PE-CGS)

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 15, 2023 | Volume: 32 | Issue: 4 | Pages: 487-495

10.1158/1055-9965.epi-22-0356 | PMID 36791345 Get It

Abstract Background: Engaging diverse populations in cancer genomics research is of critical importance and is a fundamental goal of the NCI Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Established as part of the Cancer Moonshot, PE-CGS is a consortium of stakeholders including clinicians, scientists, genetic counselors, and representatives of potential study participants and their communities. Participant engagement is an ongoing, bidirectional, and mutually beneficial interaction between study participants and researchers. PE-CGS sought to set priorities in participant engagement for conducting the network's research. Methods: PE-CGS deliberatively engaged its stakeholders in the following four-phase process to set the network's research priorities in participant engagement: (i) a brainstorming exercise to elicit potential priorities; (ii) a 2-day virtual meeting to discuss priorities; (iii) recommendations from the PE-CGS External Advisory Panel to refine priorities; and (iv) a virtual meeting to set priorities. Results: Nearly 150 PE-CGS stakeholders engaged in the process. Five priorities were set: (i) tailor education and communication materials for participants throughout the research process; (ii) identify measures of participant engagement; (iii) identify optimal participant engagement strategies; (iv) understand cancer disparities in the context of cancer genomics research; and (v) personalize the return of genomics findings to participants. Conclusions: PE-CGS is pursuing these priorities to meaningfully engage diverse and underrepresented patients with cancer and posttreatment cancer survivors as participants in cancer genomics research and, subsequently, generate new discoveries. Impact: Data from PE-CGS will be shared with the broader scientific community in a manner consistent with participant informed consent and community agreement.
Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Abu‐Rustum, Nadeem R. , Yashar, Catheryn M. , Barber, Emma L. , Bradley, Kristin , Brooks, Rebecca , Campos, Susana M. , Chino, Junzo , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Han, Ernest , Holmes, Jordan A. , Howitt, Brooke E. , Mariani, Andrea , Mutch, David, Nagel, Christa , Nekhlyudov, Larissa , Podoll, Mirna, Salani, Ritu , Schorge, John O., Siedel, Jean , Sisodia, Rachel , Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , Zanotti, Kristine , McMillian, Nicole R., Aggarwal, Shaili, Arend, Rebecca C. , Chu, Christina , Crispens, Marta Ann , Lea, Jayanthi Sivasothy , Wethington, Stephanie L.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 15, 2023 | Volume: 21 | Issue: 2 | Pages: 181-209

10.6004/jnccn.2023.0006 | PMID 36791750 Get It

Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. It is estimated that 65,950 new uterine cancer cases will have occurred in 2022, with 12,550 deaths resulting from the disease. Endometrial carcinoma includes pure endometrioid cancer and carcinomas with high-risk endometrial histology (including uterine serous carcinoma, clear cell carcinoma, carcinosarcoma [also known as malignant mixed Müllerian tumor], and undifferentiated/dedifferentiated carcinoma). Stromal or mesenchymal sarcomas are uncommon subtypes accounting for approximately 3% of all uterine cancers. This selection from the NCCN Guidelines for Uterine Neoplasms focuses on the diagnosis, staging, and management of pure endometrioid carcinoma. The complete version of the NCCN Guidelines for Uterine Neoplasms is available online at NCCN.org .
Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-analysis of Randomized Trials
Shah, Surbhi

Mayo Clinic

The Hematologist | February 15, 2023 | Volume: 20 | Issue: 2 | Pages: No page available

10.1182/hem.v20.2.202321 Get It